Trefoil Therapeutics is a biotechnology company specializing in the development of regenerative pharmacologic treatments for corneal diseases. The company's core technology platform is based on engineered fibroblast growth factor 1 (eFGF1), which is designed to stimulate the proliferation and migration of corneal endothelial cells. Trefoil's lead candidate, TTHX1114, is an engineered form of FGF1 that is being developed as an intracameral injection. This treatment aims to address endothelial dystrophy, a leading cause of cornea transplantation surgeries, by promoting the healing of corneal endothelial lesions.

Trefoil operates in the biopharmaceutical market, targeting ophthalmologists and healthcare providers who treat corneal diseases. The company's business model involves the research, development, and eventual commercialization of its proprietary treatments. Revenue is generated through the sale of these pharmacologic treatments, as well as potential partnerships and licensing agreements with larger pharmaceutical companies.

Keywords: regenerative, pharmacologic, corneal diseases, fibroblast growth factor, TTHX1114, endothelial dystrophy, intracameral injection, biotechnology, ophthalmology, biopharmaceutical.